Sequence-Specific Gene Correction of Cystic Fibrosis Airway Basal Cells by Anirudhan, Varada
The Texas Medical Center Library 
DigitalCommons@TMC 
The University of Texas MD Anderson Cancer 
Center UTHealth Graduate School of 
Biomedical Sciences Dissertations and Theses 
(Open Access) 
The University of Texas MD Anderson Cancer 
Center UTHealth Graduate School of 
Biomedical Sciences 
5-2019 
Sequence-Specific Gene Correction of Cystic Fibrosis Airway 
Basal Cells 
Varada Anirudhan 
Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations 
 Part of the Medicine and Health Sciences Commons, and the Molecular Genetics Commons 
Recommended Citation 
Anirudhan, Varada, "Sequence-Specific Gene Correction of Cystic Fibrosis Airway Basal Cells" (2019). The 
University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences 
Dissertations and Theses (Open Access). 948. 
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/948 
This Thesis (MS) is brought to you for free and open 
access by the The University of Texas MD Anderson 
Cancer Center UTHealth Graduate School of Biomedical 
Sciences at DigitalCommons@TMC. It has been 
accepted for inclusion in The University of Texas MD 
Anderson Cancer Center UTHealth Graduate School of 
Biomedical Sciences Dissertations and Theses (Open 
Access) by an authorized administrator of 















Burton Dickey, M. D. 
 
__________________________________ 
Jichao Chen, Ph.D 
 
__________________________________ 
Sheng Zhang, Ph.D 
 
__________________________________ 




        Dean, The University of Texas 






SEQUENCE-SPECIFIC GENE CORRECTION of 




Presented to the Faculty of 
The University of Texas  
MD Anderson Cancer Center 
UTHealth Graduate School of Biomedical Sciences 
in Partial Fulfillment of the Requirements 
of the Degree of 
 
MASTER OF SCIENCE 
 
By 



























      I would like to express my gratitude towards my supervisor, Dr. Brian Davis, for his 
constant support throughout the period of my master’s course. His achievements, hard 
work and humility truly inspire me; he has patiently guided me, challenging me and 
providing me the necessary criticism when required, which in turn has helped me 
develop into a much better scientist than I was before I joined his lab.  
       I would also like to thank the current and former members of my lab for all the 
guidance they have provided me during my time here and for making the lab a 
wonderful place for me to learn while also having fun doing some interesting research: 
Drs. Ana Crane, Shingo Suzuki (who has taught me a number of technical skills, for 
which I will forever be thankful), Nadine Matthias, John Avila, Cristina Barillá, and Leila 
Rouhigharabaei. I am grateful to our collaborators, Drs. Eric Sorscher and Andras Rab 
for their immense help in performing Ussing chamber studies for my project. I would like 
to thank also Dr. Anthony Conway, our collaborator at Sangamo Therapeutics, for 
performing, as part of my project, Next-Generation Sequencing analysis. Thank you Dr. 
Zhengmei Mao for your help with the histology studies for my project. 
     I would like to thank my advisory committee members Drs. Burton Dickey, Philip Ng, 
Jichao Chen and Sheng Zhang for their constant supervision throughout my project 
work. Along with Dr. Davis, each of them have been involved in improving my thinking 
abilities as a researcher. 
     Thank you GSBS, first of all, for accepting me into your MS program, and everyone 
at the GSBS office (especially Drs. Eric Swindell and Lindsey Minter), I am grateful to 
you for being so kind towards me, helping me when needed and answering so patiently 
v 
 
even my silliest questions.      
     Words cannot express how thankful I am to my mother, father and sister for their 
unconditional love and faith in me. I owe them so much; this degree is more theirs than 
it is mine. My closest friends here in Houston, Kaavya and Henry, thank you for having 
my back. Last but certainly not the least, Saravanan, my pillar of strength, thank you for 
















Sequence-Specific Gene Correction of Cystic Fibrosis Airway Basal Cells 
Varada Anirudhan, B. Tech. 
Advisory Professor: Brian Davis, PhD 
      Cystic fibrosis (CF) is a lethal monogenic disease resulting from mutations in the 
CFTR gene which encodes a protein involved in regulating anion trans-epithelial 
transport. A three-base deletion in CFTR (termed as ΔF508 mutation), wherein CFTR 
protein is misfolded leading to its pre-mature degradation in the endoplasmic reticulum 
(ER), is the most common cause of this debilitating disease. Since CFTR is expressed 
in multiple body systems, CF affects different organs, but lung pathology is the greatest 
cause of death in affected patients. We achieved site-specific gene correction with an 
efficiency of ~10 % in CF airway basal cells homozygous for the ΔF508 mutation. Basal 
cells are a multipotent stem cell population of the respiratory epithelium and therefore, 
their gene correction could provide a long-term, permanent remedy for CF. Delivery of 
engineered sequence-specific zinc finger nucleases (ZFNs) and single-stranded oligo 
DNA (ssODN) carrying the correcting sequence via electroporation facilitated the 
correction. The gene-corrected cells upon in vitro differentiation using air-liquid interface 
showed presence of fully-glycosylated mature CFTR protein as opposed to 
differentiated mutant cells which synthesized only the core-glycosylated immature form. 
Most importantly, we demonstrated CFTR ion channel activity in the gene-corrected 
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1.1 Cystic Fibrosis (CF) 
 
     A lethal recessive autosomal disease, cystic fibrosis (CF) is common in populations 
of northern European descent with an incidence rate of about 1 in 2000 births (2). 
Mutations in the gene that encodes the cystic fibrosis transmembrane regulator (CFTR) 
protein results in CF. Less than 200 mutations among the ~2000 that have been 
identified in the CFTR gene have been demonstrated to result in CF (2). Based on their 
impact at the cellular level, the CFTR mutations fall into six distinct classes (TABLE 
1.1). The most common CFTR mutation (∆F508), comprising 66% of all mutations, 
belongs to class II and causes the deletion of phenylalanine at position 508 of CFTR. 
The ∆F508 CFTR protein is improperly folded leading to its retention in the endoplasmic 
reticulum (ER) and eventual degradation by the proteasome in a ubiquitin-dependent 
fashion which drastically reduces protein delivered to the cell surface (7). CFTR channel 
opening is also defective in ∆F508 CF patients (15). The CFTR gene is located on 
chromosome 7, has 27 exons and the three-base-pair ∆F508 deletion occurs in  
exon 11. 
1.1.1 CF Pathophysiology  
     CFTR functions as an anion channel primarily for chloride and bicarbonate transport. 
In CF patients, the epithelial cells are characterized by decreased chloride secretion 
and increased sodium absorption (4). Although CF affects multiple organs including the 
lungs, pancreas, liver, intestine, bones and male reproductive tract (2), the pulmonary 
manifestations are the major cause for CF morbidity and mortality (3). This is because 
the regulatory role of CFTR to balance salt and fluid transport is disrupted leading to 
thick and sticky mucus being produced along the airway which paves the way for micro-
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organisms to invade and infect the lung (14). CF lung infection is mainly caused by 
Staphylococcus aureus, Hemophilus influenza, and Pseudomonas aeruginosa (4). 
Other CF symptoms include maldigestion, and fat & protein malabsorption resulting 
from pancreatic insufficiency (occurring in 90% of CF patients) (5), gastroesophageal 
reflux (4) and symptomatic cholelithiasis (occurring in ~5% of CF patients) (6). 
1.1.2 CF Treatment  
    The median survival when CF was first described in 1938 (8)  was less than 1 year of 
age and now it is 46.2 years in the United States (9) and 41 in the UK (2) owing to early 
detection and improved treatment methods. Frequent prolonged courses of antibiotic 
treatment help improve pulmonary function (10). Viral infection in the respiratory tract 
can be prevented with the help of vaccination against measles, chicken pox and 
influenza. Standard chest physical therapy, mechanical vests and directed exhalation 
techniques aid in controlling airway obstruction (4). Treatment using aerosolized 7% 
hypertonic saline solution has shown clinically-relevant benefits in ameliorating CF 
symptoms (93, 94).  
     CFTR modulators are therapeutic small molecules that have proved beneficial to a 
growing number of CF patients (11, 12, 13) and include “CFTR potentiators” which 
increase epithelial CFTR activity & “CFTR correctors” that improve defective protein 
misfolding and trafficking. The primary target of the CFTR potentiator Kalydeco® 
(ivacaftor, IVA; Vertex Pharmaceuticals, Boston, MA, USA) is a Class III CFTR mutation 
known as G551D in which CFTR channel has a lower open probability than wild-type 
CFTR. Orkambi® (Vertex Pharmaceuticals, Boston, MA, USA), an agent containing two 
compounds including lumacaftor and IVA (also known as VX809 and VX770), increases 
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CFTR protein deposition on cell surfaces by acting as molecular chaperones during 
protein folding and has shown promising results in treating ∆F508 CF. Currently, in late-
stage clinical trials are three-drug combination (VX-659 + tezacaftor + ivacaftor) 
potentially capable of treating up to 93% of CF patients, including those with the ∆F508 
mutation in at least one allele (88).The CFTR modulators, however, are expensive, and 
require lifetime treatment (16).  
TABLE 1.1 The six classes of CFTR mutations and their respective phenotypic 
defects: 
Class Defect Example 
I defective protein production Gly542X 
II defective protein processing ∆F508 
III  defective channel regulation G551D 
IV defective conduction Arg117His 
V reduction in functional CFTR protein 2789 + 5G 
VI decreased CFTR stability 4326delTC 
 
1.2 Airway Basal Cells (BCs) 
   The lung originates from the foregut endoderm and has two major regions: the 
airways which conduct gases and the alveoli where gas exchange occurs. Although it 
includes mesenchymal, endothelial and neural compartments, the epithelial cell 
lineages of the lung have been best-characterized. Most of these studies have been 
conducted, however, in the murine lung and therefore it is important to note that the 
human lung may have additional unique properties that are yet to be studied.  
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   In the proximal lung region, the upper airways and bronchi (comprising large airway 
region) contain superficial epithelium and submucosal glands. Small or distal airways 
(bronchioles) contain only superficial epithelium. The lung epithelium in large airways is 
pseudostratified and is composed mainly of basal (BC), secretory, and ciliated cells (37) 
and rare neuroendocrine cells (51). Cytokeratin 5 (CK5) and 14 (CK14) preferentially 
expressed in the basal cells help them firmly attach to the basement membrane via 
hemidesmosomes (38). This property contributes to the structural role of basal cells 
wherein they help tether the columnar epithelial cells to the airway wall (47). They also 
characteristically express the transcription factor Tp63 (p63) (45) and nerve growth 
factor receptor (NGFR) (39). Boers et al. (1998) (37) showed that the distribution of 
airway basal cells varies along the length of the airways with ~31% basal cells in the 
largest conducting airways (diameter ≥ 4 mm) and 6% in the smallest airways (diameter 
< 0.5 mm). Based on several studies (39, 40, 41, 42), there is now evidence that the 
airway BCs are a multipotent stem cell population. Firstly, Randell et al. (2000) (43) 
suggested the existence of stem-cell niches in the pseudostratified epithelium of mouse 
trachea based on BrdU (bromodeoxyuridine/5-bromo-2’deoxyuridine) label retention 
over long term after epithelial cell damage by SO2 inhalation. Hong and colleagues 
(2003) (44) demonstrated that CK14-expressing basal cells proliferate and re-establish 
the normal epithelium in vivo following naphthalene-induced secretory cell depletion. 
Hajj et al. (2007), using an in vivo humanized nude mouse xenograft model and an in 
vitro air‐liquid interface culture model, demonstrated the ability of human airway basal 
cells to restore a well-differentiated and functional airway epithelium. Similar studies 
were conducted by Peault B. et al (2005) (48) as well. Later in 2009, Rock et al. (39), 
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through lineage-tracing studies in mouse trachea, demonstrated the ability of basal cells 
in steady state to self-renew and differentiate to secretory and ciliated cells. With the 
help of a novel 3-dimensional sphere forming assay, they were able to demonstrate that 
BCs of both mouse trachea and human airways are a multipotent stem cell population.  
    Airway basal cells can be expanded in vitro using a technique involving co-culture 
with irradiated 3T3-J2 feeder cells along with a Rho-associated protein kinase (ROCK) 
inhibitor Y-27362 (49, 50). These cells were demonstrated to maintain their tissue-
specific stem cell features in that they proliferated and differentiated to secretory and 
ciliated cells. Mou et al. assessed the roles of transforming growth factor-β (TGF-β) and 
bone morphogenetic protein (BMP) signaling in epithelia and demonstrated that 
inhibition of these signaling pathways along with a ROCK inhibitor (termed ‘dual SMAD 
inhibition’ media) aided in the long-term expansion of airway basal cells (1). 
1.3 CFTR Expression in the Airway Epithelia 
    Although CFTR plays a vital role in maintaining normal physiology of lung epithelial 
cells, it is expressed at very low levels (1-2 CFTR mRNA transcript copies per cell) (52). 
This, along with the low specificity of CFTR antibodies are probably the reasons why 
studies to elucidate cellular localization of CFTR have shown contradictions. Engelhardt 
et al. (1992) (54), using in situ hybridization and immunofluorescence studies 
demonstrated that in the human bronchus the predominant site of CFTR expression 
was the submucosal glands and rare (1-3% of total cell number) “flask-like” cells 
present in the submucosal gland ducts. In another study (1994) (53), similar 
observations were reported; in addition, they showed that CFTR expression was 
undetectable in the ciliated cells although they are believed to be involved in trans-
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epithelial ion transport. Kreda and colleagues (55) detected CFTR mRNA throughout 
the lung superficial epithelium and found that the expression level decreased distally. 
Using immunostaining and high-resolution laser confocal microscopy techniques they 
showed that CFTR was localized to the apical region of the ciliated cells. They also 
observed rare cells that were intensely stained by CFTR antibodies.  
    Most recently, two groups (51, 56) identified a new rare lung epithelial cell population 
which highly expresses CFTR. These cells, named as pulmonary ionocytes, specifically 
expressed FOXI1 transcription factor and CFTR, comprise <1% of total lung epithelial 
cells and expressed 54.4% of all detected CFTR mRNA. These results were based on 
single-cell RNA sequencing analysis on mouse tracheal epithelial cells and in vitro-
differentiated primary human bronchus epithelial cells (HBECs). However, there is 
currently no consensus regarding the relative roles for ionocytes versus ciliated cells in 
functional CFTR activity in the airways. 
1.4 Programmable Nuclease-mediated Gene Therapy 
      The inherent response of a cell to double-stranded DNA breaks (DSBs) is to follow 
either of the two endogenous DNA repair pathways: non-homologous end-joining 
(NHEJ) and homology-directed repair (HDR) (22). The error-prone NHEJ mechanism 
results in the creation of insertions and/or deletions of nucleotides (known as INDELs) 
which can result in a gene ‘knock-out”. In the presence of a donor DNA, the cell can 
follow the HDR pathway to ‘edit’ or ‘correct’ the genome in the desired way.  
   Zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), 
and Clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) are three 
8 
 
nuclease systems that have proved their potential to enable genome editing (23). Each 
of these programmable nucleases results in induction of sequence-specific double-
stranded DNA breaks (DSBs). This forms the basis for nuclease-mediated gene 
therapy.  
1.4.1 ZFN-mediated Gene Therapy 
         ZFNs are targetable DNA cleavage reagents that are fusions of a DNA-binding 
domain and a non-specific FokI endonuclease cleavage domain (FIGURE 1.1). The 
DNA-binding domain includes zinc finger (ZF) motifs which are engineered to 
specifically bind to the target sequence of interest and their DNA recognition ability is 
context-dependent.  
   The ZFN monomers (ZFN-L and ZFN-R) are inactive by themselves and it is required 
that two ZFN monomers bind to their adjacent DNA sites and the FokI nuclease 
domains to dimerize for the ZFN to cause double-stranded DNA breaks (33). This 
property served as an advantage to improve ZFN specificity to avoid off-target cleavage 
and three research groups (34, 35, 36) re-designed the FokI domains (making them 
obligate heterodimers) permitting cleavage only by ZFN-L/ZFN-R (and not ZFN-L/ZFN-L 
or ZFN-R/ZFN-R) by which they were able to considerably reduce cytotoxicity resulting 
from promiscuous cutting by the ZFNs.  
    Sequence-specific gene targeting can be achieved using ZFNs and has been shown 
by several studies including that of Porteus (2005) (27) where one site each in β-globin 
and the interleukin-2 receptor common gamma chain (IL-2Rγ) were targeted. Later, the 
Sangamo Biosciences group designed ZFN pairs that mediated targeting of the hamster 
dihydrofolate reductase (DHFR) gene (28) and the human chemokine receptor CCR5 
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gene (29). These are examples of gene inactivation where the cell’s NHEJ machinery 
resulted in gene knock-out. 
    As noted earlier, to add nucleotide sequences, or to ‘correct a gene sequence’ 
requires the introduction of a donor DNA carrying the correcting sequence along with 
the DSB-inducing nuclease such as ZFNs. Urnov et al. (2005) (31) had achieved an 
18% gene correction of an X-linked severe combined immunodeficiency (SCID) 
mutation in the IL-2Rγ gene using site-specific ZFNs. Moehle et al. (2007) (30) achieved 
5-15% targeted integration in the exon 5 region of the human IL-2Rγ gene using site-
specific ZFNs and donor DNA. Both of these studies reported selection-free gene 
modification and used double-stranded DNA as donors. Chen et al. (2011) reported 
evidence for efficient genome editing using ZFNs and single-stranded DNA oligos 
(ssODN) where the efficiency of insertion was in the range 7% to 57% and showed that 
these values were cell-type dependent (32). 
1.4.2 Gene Therapy in Stem Cells  
    Stem cells possess self-renewal and multi-lineage differentiation potential which 
makes them suitable for regenerative medicine. Several groups have reported 
successful ex vivo viral-based gene delivery (with random integration of therapeutic 
transgenes) in hematopoietic stem cells (HSCs) from patients with genetic diseases 
such as Wiskott-Aldrich syndrome (17, 18), X-linked severe combined 
immunodeficiency (SCID) (19) and β-thalassemia (20).  Efficient gene editing to ablate 
two clinically relevant genes CCR5 and B2M was achieved in HSCs using a 
CRISPR/Cas9 nuclease system (21). 
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FIGURE 1.1 Action of Zinc Finger Nucleases: Shown here  
is a pair of ZFN monomers that result in DSBs upon binding  
of their DNA-binding domain (orange) to the respective DNA  
sequences and dimerization of the FokI-endonuclease domains  
(yellow). In the presence of a donor DNA, the cell’s DNA repair  
pathway can follow homology-directed repair facilitating targeted  
gene replacement (green), otherwise non-homologous end  
joining pathway would be followed resulting in insertions (blue)  
and deletions (red) (INDELs). 
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One of the first reports to demonstrate the potential of ZFNs to induce specific 
homology-repair mediated gene targeting in human induced pluripotent stem cells 
(hiPSCs) and human embryonic stem cells (hESCs) was by Zou and group (32) where 
they corrected a mutant GFP reporter gene at an efficiency of 0.14-0.24 %. Specific 
targeting of the OCT4 (pluripotency-associated) gene in hESCs using zinc finger 
nucleases with an efficiency of 39-100 % was demonstrated (70). This study also 
reported ZFN-mediated targeting of the ubiquitously-expressed PPP1R12C gene and 
the gene encoding PITX3 transcription factor with efficiency ranges of 33-56% and 
~11% in hESCs and hiPSCs, respectively.  
1.5 CF Gene Therapy 
    Soon after the CFTR gene was cloned in 1989 (59, 60, 61), extensive research 
commenced to cure CF using gene therapy techniques and several studies have 
reported viral and non-viral techniques to facilitate CF gene therapy. Two groups (62, 
63) demonstrated restoration of chloride ion defect using CFTR-expressing viral vectors 
and were among the first studies to show proof-of concept for CF gene therapy. More 
recently, CF gene therapy studies using adeno-associated viral vectors and lentiviral 
vectors (64, 65, 66, 67) have focused more on solving viral tropism issues and reduce 
host immune response, apart from trying to enhance CFTR expression levels.  
   In addition to delivering wild-type CFTR-expressing vectors, sequence-specific gene 
correction has also been performed. Lee et al (68) used ZFN expression plasmids and a 
donor plasmid containing 4.3 kb of WT CFTR sequence to repair the ΔF508 mutation 
and obtained an overall efficiency of < 1%. They reasoned that the low repair level was 
a consequence of the distance (203 bp) of the deletion mutation (CTT) from the ZFN 
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target site. Induced pluripotent stem cells (iPSCs) derived from CF patient fibroblasts 
were corrected for the ΔF508 mutation using ZFNs and a selectable plasmid donor; in 
vitro differentiation of the iPSCs towards lung lineages showed presence of fully-
glycosylated CFTR protein and correction of the chloride ion defect (Crane et al) (69).  
1.5.1 What Efficiency of CFTR Gene Editing is Required to Restore 
Therapeutically Relevant Levels of CFTR Channel Function? 
     It is important to note that since CF is a recessive disease, if correction is achieved 
in only one CFTR allele per cell that essentially recreates the carrier state. 
     Studies by Trapnell et al. (52) showed that very low levels of CFTR at 1-2 copies per 
cell are expressed in the human nasal, tracheal and bronchus epithelium because of the 
endogenous CFTR promoter being weak. This observation, in addition to the fact that 
phenotypically normal CFTR heterozygotes express 50% abnormal CFTR mRNA 
transcripts, leads to the prediction that low CFTR expression may be sufficient for 
restoring CF lung epithelial functions to wild-type. Johnson et al. (56) reported that as 
few as 6-10% corrected cells was sufficient to restore CF chloride ion transport levels to 
normal. A study using the in vivo xenograft technique showed that 5% of 
pseudostratified epithelial cells expressing CFTR corrected the CF chloride transport 
defect (58). These two studies used highly-efficient viral vector promoters to express 
CFTR and therefore it cannot be assured that comparable results would be obtained in 
differentiated human airway epithelia where CFTR is under the control of its 
endogenous promoter. To address this issue, in a set of cell mixing experiments where 
freshly-isolated wild-type and CF (carrying homozygous ∆F508 mutation) airway 
epithelial cells were mixed in varying proportions and in vitro differentiated using air 
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liquid interface method; Farmen et al. (57) demonstrated that 20% wild-type cells 
generated 70% trans-epithelial chloride current relative to airway epithelia containing 
100% wild-type cells. This indicates that in order to correct chloride transport defect in 
CF cells, a small fraction of CFTR-expressing cells is sufficient (57). However, the 
clinical implications of these results are not yet known.  
1.6. Objectives and Hypothesis 
   We hypothesize that ∆F508 gene correction in CF airway basal cells can restore 
normal proximal airway epithelial cell function. To test this, we aimed to accomplish the 
following aims: 
1.6.1 Specific Aim I: Site-specific zinc finger nucleases-mediated gene 
correction of ∆F508 mutation in CF airway basal cells carrying ∆F508/∆F508 
mutation: ∆F508 mutation-specific ZFNs were delivered in the form of 
messenger RNA (mRNA) via electroporation along with single-stranded DNA 
oligo (ssODN) carrying the correcting sequence to facilitate gene correction of 
CF airway basal cells. In order to assess the % genome modification, including % 
NHEJ and % gene correction, PCR followed by TIDER (Tracking of Insertions 
Deletions and Recombination Events) analysis and Next Generation Sequencing 
analysis were performed.  
1.6.2 Specific Aim II: Demonstration of CFTR functional restoration in gene 
corrected-basal cells at the protein and ion channel function levels: Gene 
corrected-airway basal cells were in vitro differentiated into airway 
pseudostratified epithelium using air liquid interface system. In order to 
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demonstrate restoration of CFTR ion channel function in these cells, 
electrophysiology analysis was performed using the Ussing chamber system. 
Western blot analysis was used to show presence of fully-glycosylated CFTR 
protein in the corrected cells. 
 
The approach described in this study to site-specifically correct CFTR ∆F508 could be 
utilized for the following potential therapeutic approaches: 
a) Edit the ∆F508 mutation in patient-derived airway basal cells ex vivo with an eventual 
aim to transplant the treated cells (as a bulk mixture of edited and non-edited cells or as 
expanded homogenous single-cell derived clone) back into the patient; since this is an 
autologous method of therapy, there is minimal risk of systemic immunological reactions 
in the host, (or) 
b) Accomplish in vivo correction of ∆F508 mutation in airway basal cells.  
It is important to note that since CF is a recessive disease, if correction is achieved in 
only one CFTR allele the patient would now be a CF carrier, i. e., they would be relieved 





























2.1 Airway Basal Cells: Origin & Culturing 
       CF ∆F508/∆F508 and non-CF airway basal cells were provided to us by Dr. Scott 
Randell (University of North Carolina, NC, USA). Basal cells were cultured on plates 
pre-coated with ‘804G-conditioned medium’ and incubated at 37 ºC in humidified air 
with 5% CO2. To prepare the 804G-conditioned medium, the 804G cell line (a rat 
bladder epithelial cell line) kindly given to us by Dr. Hongmei Mou (Massachusetts 
General Hospital, Boston, MA, USA) was cultured in RPMI-1640 (Sigma Aldrich) 
supplemented with 10 % Fetal Bovine Serum (FBS) (HyClone) and 1% Penicillin-
Streptomycin (pen-strep) (Gibco) on 100 mm TC-treated culture dish (Corning®) until 
they were confluent. Cells were then passaged and cultured on 225cm² culture flask 
(Falcon®) at an initial seeding of 4 million cells per flask containing 50 ml medium. They 
were cultured at 37 ºC in humidified air with 5% CO2.  After the cells were confluent, 
medium was replaced with 100 ml fresh medium, and every alternate day the medium 
was collected and replaced with fresh medium, for up to 3 collections. Medium obtained 
was filter-sterilized and stored at 4 ºC. 
       Basal cells were cultured in either the ‘dual SMAD inhibition medium (1) or 
Pneumacult™-Ex Plus medium (STEMCELL Technologies), both containing 1% pen-
strep. Dual SMAD inhibition medium consisted of SAGM™ medium (Lonza) 
supplemented with 10 µM RhoA kinase (ROCK) inhibitor Y27362 (Reagents Direct), 1 
µM A-8301 (R&D Systems), 1 µM DMH-1 (R&D Systems) and 1 µM CHIR99021 (R&D 
Systems); all four supplements were re-suspended in DMSO and stored at -20 ºC. 
Medium was replaced on a daily basis. The cells cultured in Pneumacult™-Ex Plus 
medium were fed fresh medium every alternate day until they reached ~50% confluence 
17 
 
after which they were fed daily. To passage the basal cells, they were split in the ratio 
1:10 after dissociation with 0.25% trypsin (Lonza) for 5-8 minutes followed by the 
neutralization of trypsin by RPMI-1640 + 10% FBS.  
         To freeze the cells (basal or 804G), they were re-suspended in CryoStor® cryo-
preservative medium (STEMCELL Technologies) and kept frozen in liquid N2. 
2.2 Characterization of Airway Basal Cells 
      Airway basal cells were characterized for basal cell-specific surface markers CD49f 
and NGFR using fluorescence analysis. 200,000 cells were incubated on ice (protected 
from light) for 30 minutes with αCF49f-PE (Biolegend) and/or αCD271-APC (Biolegend) 
(TABLE 2.1) in 100 µl of FACS buffer (phosphate buffered saline with 1% FBS).  Non-
immune IgG2a-PE and IgG1, κ-APC were used as isotype controls. Antibody-stained 
cells were washed with FACS buffer and pelleted by a 5-minute centrifugation at 200g 
and then re-suspended with FACS containing 0.075 µg/ml 4’,6-diamidino-2-phenylindole 
(DAPI) (Life Technologies) for live cell separation.  Two different lasers were used to 
excite the phycoerythrin (PE) (568 nm) and allophycocyanin (APC) (633 nm) fluors. 
Stained cells were analyzed on a FACS LSRII (BD Biosciences) using FACS DiVA 
software (BD Biosciences). 
2.3 ZFN mRNA Production In Vitro 
      Exon 11 set 1 and set 2 ZFN plasmids were designed and provided by Sangamo 
Therapeutics and ZFN messenger RNAs (mRNAs) were synthesized by in vitro 
transcription using mMESSAGE mMACHINE™ T7 Ultra Transcription kit (Invitrogen). 
Briefly, template DNA was prepared by PCR amplification of 100 ng ZFN plasmid using 
the primers N80pt and R560 (TABLE 2.2) and enzyme AccuPrime™ Pfx DNA 
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Polymerase (Invitrogen). PCR conditions were as follows: an initial denaturation at 95 
ºC for 3 minutes; 30 cycles of 95 ºC for 30 seconds denaturation, 63.6 ºC for 30 
seconds annealing; 68 ºC for 2 min extension; a final extension at 68 ºC for 3 min. The 
PCR product was purified by Agencourt AMPure XP (Beckman Coulter) following the 
manufacturer’s instructions. The purified PCR product was used to generate mRNA with 
mMESSAGE mMACHINE™ T7 Ultra Transcription kit (Invitrogen), followed by RNA 
purification by MEGAclear™ Transcription Clean-Up kit as per the manufacturer’s 
instructions. The quantity and quality of the RNA was assessed by Qubit™ RNA HS 
Assay kit and Agilent Bioanalyzer, respectively. 
 










CD49f Clone: GoH3 
Biolegend rat 313612 1:1000 
PE isotype  mouse IgG2a Invitrogen mouse MG2A04 1:1000 
APC anti human CD271 
(NGFR) clone ME20.4 
Biolegend mouse 345108 1:1000 
APC mouse IgG1,𝛋 
isotype  Ctr MOPC-21 
Biolegend mouse 400121 1:1000 
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TABLE 2.2 List of primers used in this study 
Primer 
Name 
Purpose Primer Sequence (5' to 3') 
N80pt ZFN mRNA 
production 
GCAGAGCTCTCTGGCTAACTAGAG 





#49 exon 11-Cel 1 Assay GTAGTGTGAAGGGTTCATATGC 
#50 exon 11-Cel 1 Assay GGAGGCAAGTGAATCCTGAG 
#85 PCR for Sanger 
Sequencing 
CTATCTGAATCATGTGCCC 










PCR for Sanger 
Sequencing 
TACGAGTGGAAAAGTTGCGGA 
























CF17Fw RT-PCR AGGGATTTGGGGAATTATTTG 
















    Addition of the WPRE sequence to the ZFN plasmid was done by Dr. Ana Maria 
Crane, a senior research scientist in our lab. Briefly, WPRE sequence was PCR-
amplified and cloned into the ZFN plasmid at XhoI and XbaI restriction enzymes site. 
2.4 Transfection of Gene Editing Reagents 
       100 and 200-mer single-stranded oligo DNA was synthesized by Integrated DNA 
Technologies.  
Sequence of the 100-mer ssODN (5’ – 3’): 
TGTTCTCAGTTTTCCTGGATTATGCCTGGCACCATTAAAGAAAATATCATCTTTGGTGTTTC
CTATGATGAATATAGATACAGAAGCGTCATCAAAGCATGCC.  





      All the gene editing reagents (ZFN mRNAs and ssODN), and when applicable, 
TriLink CleanCap® EGFP (Enhanced Green Fluorescent Protein) mRNA, were 
transfected in to basal cells via electroporation using the BTX™ ECM 830 
electroporation generator (Harvard Apparatus). The cells were harvested for 
electroporation using 0.25% trypsin (Lonza) (5-8 minutes), followed by the neutralization 
of trypsin with 10% FBS (HyClone) and then cells were washed once with phosphate 
buffered saline (PBS). Cells were pelleted by a 5-minute centrifugation at 200g and then 
re-suspended in BTXpress™ solution (Harvard Apparatus) to a final concentration of 
0.5 X 106 cells per 100 µl of solution. Appropriate volumes of the gene targeting 
reagents or EGFP mRNA were added to this cell suspension and electroporation was 
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done in BTX™ electroporation cuvettes (2mm gap, Harvard Apparatus) at Low Voltage 
(LV) conditions of 250 V for 5 ms, 1 pulse. Immediately after electroporation, the cells 
recovered by adding 550 µl of medium (dual SMAD inhibition or Pneumacult™-Ex Plus) 
to the cuvette were equally distributed between 2 wells of a 6-well clear flat-bottomed 
plate (Falcon®) pre-coated with 804G-conditioned medium. Three days post 
electroporation, cells were harvested for DNA isolation, and/or expansion for further 
studies.  
2.5 Assessment of % Genome Modification 
        For the Cel 1 assay (FIGURE 2.1), 100 ng genomic DNA (gDNA) isolated from 
transfected cells using GeneJET Genomic DNA Purification kit (Thermo Scientific) was 
PCR-amplified using primers #49 and #50 and the enzyme Phusion High-Fidelity DNA 
Polymerase (Thermo Scientific). PCR conditions were as follows: an initial denaturation 
at 98 ºC for 30 seconds; 35 cycles 98 ºC for 10 seconds denaturation, 68 ºC for 20 
seconds annealing, 72 ºC for 15 seconds extension; a final extension at 72 ºC for 10 
minutes. The PCR product was purified by Agencourt AMPure XP (Beckman Coulter). 
Denaturation of the amplicon at 98 ºC for 10 min was followed by re-annealing (95 ºC to 
85 ºC at the rate 2 ºC per second, 85 ºC to 25 ºC at the rate 0.1 ºC per second) and 
subsequent incubation with surveyor nuclease enzyme (IDT) at 42 ºC for 20 min. ZFNs 
cause double-stranded DNA breaks (DSB) that are sealed by the cell’s inherent error-
prone repair mechanism termed non-homologous end joining (NHEJ) which cause 
nucleotide insertions and deletions (INDEL). The surveyor enzyme detects and cleaves 
nucleotide mismatches that results from ∆F508-INDEL or INDEl1-INDEL2 hetero-duplex 
formation after the denaturation-renaturation step. The cleaved DNA products were 
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resolved on a 10 % TBE gel (Invitrogen).  
        TIDER is a bioinformatics tool (https://tider.deskgen.com/) which we had used 
extensively in this study for the purpose of assessing % NHEJ and % gene correction. 
TIDER uses as its input Sanger sequence data constituting a mixture of sequences and 
decomposes into individual sequences with calculated frequencies (89). DNA from 
transfected and non-transfected control cells were PCR-amplified using primers 
CFi10aFw & CFi11aRv and after purification of PCR products (Macherey-Nagel 
NucleoSpin Gel and PCR Clean-Up kit), Sanger sequencing was done by Lone Star 
Labs (Houston, TX, USA) using the primer CF5. PCR conditions were as follows: an 
initial denaturation at 95 ºC for 2 minutes; 35 cycles 94 ºC for 30 seconds denaturation, 
57 ºC for 30 seconds annealing, 72 ºC for 1 minute extension; a final extension at 72 ºC 
for 5 minutes. The ‘guide sequence’ for the TIDER analysis was 5’- 
AATATCATTGGTGTTTCCTA; control and reference chromatogram for the analyses 
were sequences from CFTR ∆F508/∆F508 and non-CF DNA, respectively. DNA from 
CFTR ∆F508/∆F508 and non-CF cells were PCR-amplified and sequenced together 
with samples in the same reaction. 
    Next Generation Sequencing (NGS) was done by our collaborator, Sangamo, where 
they used primers Miseq-Fw and Miseq-Rv for the sequencing purpose. 
2.6 Isolation and Genotyping of Single-Cell Derived Clones 
        Flat-bottomed-96-well plate (Falcon) was first pre-coated with 1% collagen 
(PureCol ® from Advanced BioMatrix), after which 30,000 ATCC-irradiated NIH3T3 
fibroblasts per well per 30 µl of complete DMEM medium was added. Complete DMEM 
medium included DMEM (Gibco), 10% FBS (HyClone), 1 % pen-strep and 1 % 
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GlutaMAX (Gibco). The next day, to each well containing mouse fibroblast feeder layer, 
airway basal cells were added at the cell density of 1 cell per well or 5 cells per well and 
cultured thereafter in the conditionally-reprogrammed cell (CRC) medium at 37 ºC in 
humidified air with 5% CO2. CRC medium was composed of complete DMEM medium, 
F-12 Nutrient Mix (Gibco), hydrocortisone (Sigma) (25 ng/ml), EGF (Invitrogen) (0.125 
µg/ml), insulin (Sigma) (5 µg/ml), fungizone/amphotericin B (Fisher) (250 ng/ml), 
Gentamicin (Gibco) (10 µg/ml), cholera toxin (Sigma) (0.1 µM) and ROCK inhibitor Y-
27362 (Reagents Direct) (10 µM).  The cells were monitored daily to confirm that a 
basal cell colony emerged from single cell and the wells that contained multiple colonies 
were omitted from further studies. After 5-8 days of initial seeding, when single-cell 
clones were greater than 50 % confluent, they were harvested using the method of 
differential trypsinization, which involved initial trypsinization using 0.05 % trypsin 
(Gibco) for 15-30 seconds to detach and remove the fibroblasts, followed by 
detachment of basal cell clones using 0.25% trypsin (Gibco) for 5-8 minutes. Each clone 
was then seeded on to one well of an 804G-coated 48-well plate (Falcon) and cultured 
in the dual SMAD inh medium. After they were ~70% confluent, each clone was 
replicated into one well of a 48-well plate (Falcon) (1:4) and one well of a 12-well plate 
(Falcon) (3:4). The cells from the 48-well plate were harvested for DNA isolation and 
subsequent allele-specific PCR (AS-PCR) and Sanger sequencing analyses  
         For AS-PCR, 100 ng DNA (isolated using Macherey-Nagel NucleoSpin Tissue XS 
kit) from each clone was PCR-amplified using the primer pairs CF1B/CF7C (wild-type-
specific) and CF1B/CF8C (ΔF508 mutant-specific) and MyTaq™ polymerase enzyme 
mix (Bioline). The PCR conditions were as follows: initial denaturation at 95 ºC for 2  
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FIGURE 2.1 Schematic of Cel 1 Assay: Three days post- 
transfection with ZFN, DNA PCR amplification followed by  
denaturation and subsequent renaturation results in DNA  
mismatches (as a result of ∆F508-INDEL or INDEL1-INDEL2  
hetero-duplex formation) that are detected and cleaved by  
surveyor nuclease enzyme.  Shown in red and blue are  
insertions and deletions (INDELs) resulting from the DSB  
induced by ZFNs followed by the error-prone NHEJ DNA  






























10% TBE gel 
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minutes; 35 cycles of 95 ºC for 30 seconds denaturation, 60 ºC for 30 seconds 
annealing, 72 ºC for 1 minute extension; a final extension at 72 ºC for 5 minutes. The 
PCR amplicon products were separated on a 1.4% agarose gel 
        For the purpose of Sanger sequencing, 100 ng DNA from each clone was PCR-
amplified using the primers #85 and #88 and GoTaq™ Hot Start polymerase enzyme 
mix (Promega). The PCR conditions were as follows: initial denaturation at 95 ºC for 2 
minutes; 35 cycles of 94 ºC for 30 seconds denaturation, 57 ºC for 30 seconds 
annealing, 72 ºC for 1 minute extension; a final extension at 72 ºC for 5 minutes. The 
amplicon products were purified using Nucleospin® Gel and PCR clean-up kit 
(Macherey-Nagel) and Sanger sequencing was done by Lone Star Labs (Houston) 
using primer #88. 
2.7 In vitro Differentiation of Basal Cells by Air Liquid Interface (ALI) System 
      Airway basal cells were seeded on to the top chamber of a 6.5 mm Transwell® with 
0.4 µm pore polyester membrane inserts (Corning) which were pre-coated with 804G-
conditioned medium. 200,000 cells was initially seeded and were cultured in dual SMAD 
inhibition or Pneumacult™-Ex Plus medium, added to the top and bottom chambers 
until the cells were 100% confluent after which, medium was replaced by Pneumacult-
ALI medium (Stemcell Technologies) containing 1% pen-strep (Gibco). The next day, 
medium from the top chamber was removed to establish air-liquid interface and the cells 
were cultured this way for 4 weeks with daily feeding.  
2.8 CFTR RT-PCR 
        Total RNA was isolated from ALI-cultured cells using NucleoSpin RNA Plus kit 
(Macherey-Nagel) and cDNA synthesis was done using ImProm-II reverse transcriptase 
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(ImProm-II Reverse Transcription System, Promega) after combining RNA with 
Oligo(dT)15 primer.  CFTR RT-PCR was performed with primers CF17Fw and 
CFex1314Rv and AccuPrime™ Pfx DNA Polymerase enzyme. RT-PCR of GAPDH with 
primers 52-GAPDH-Fw and 53-GAPDH-Rv was done as a control. PCR conditions were 
as follows: an initial denaturation at 94 ºC for 2 minutes; 35 cycles 94 ºC for 15 seconds 
denaturation, 55 ºC for 15 seconds annealing, 68 ºC for 45 seconds extension; a final 
extension at 68 ºC for 2 minutes. 
2.9 Histology and Immunofluorescence Studies 
      Hematoxylin & eosin (H&E) staining was done by Dr. Zhengmei Mao (Microscopy 
Core Facility, UTHealth).  
     Immunofluorescence study was performed on cryo-section of cells cultured in air-
liquid interface membrane inserts. Briefly, the samples were fixed with 4 % 
paraformaldehyde (PFA) (Electron Microscopy Sciences) in PBS at 4 ºC overnight after 
thorough washing with PBS. The cells were then washed thrice with ice-cold PBS, 5 min 
each. After cryopreservation using sequential sucrose treatment (first 15%, then 30 % 
sucrose in PBS, for 60 min each), the insert, after removal from the transwell using a 
clean surgical blade, was incubated in OCT embedding medium (Fisher) for 5 min and 
then transferred into a cryomold (Andwin Scientific) and flash frozen in OCT with dry 
ice. Sectioning was performed (5-8 µm) using Leica® CM1850 Cryostat and the cryo-
section was dried overnight. For immunostaining, the sectioned samples were first 
hydrated with PBS (5 min), permeabilized with 0.25 % Triton X-100 (Sigma) in PBS for 
15-30 min and blocked with 2 % bovine serum albumin (BSA) for 1 hour. Samples were 
then incubated with primary antibodies in 2 % BSA (TABLE 2.3) overnight at 4 ºC, 
28 
 
followed by three washes with PBS, 5 min each. They were then incubated with the 
respective secondary antibodies in 2 % BSA (TABLE 2.4) at room temperature for two 
hours. Followed by three 5 minute-washes in PBS, Prolong™ Gold Antifade Mountant 
with DAPI (Invitrogen) was added to counter-stain and mount the samples and the 
samples were cured for 24 hours. For H&E and immuno-staining, images were acquired 
using Leica DMi8 microscope (Leica Microsystems) and Leica Application Suite 
Software (Leica Microsystems).       
      For the purpose of relative quantification of the epithelial cell type, for each antibody 
staining, images were captured from three random fields. In each of the field, the 
number of each cell type (indicated by their respective immunostaining) was counted 
relative to the total number of cells (indicated by nuclei staining by DAPI).  
2.10 CFTR Western Blot Analysis  
       ALI-cultured cells were lysed using RIPA Lysis and Extraction Buffer (Pierce) after 
washing the inserts thoroughly with PBS. To obtain protein extracts, the cells were flash 
frozen and thawed twice, and centrifuged at 3000 g for 10 min (4 ºC) to collect the 
supernatant containing protein. The protein concentration was determined using the 
colorimetric BCA assay (Pierce). The protein samples were then prepared for 
separation by gel electrophoresis in the following way: Sample Reducing Agent 
(NuPAGE) and Sample Buffer (NuPAGE) was added to 60 µg of the protein 
supernatant, and the total volume was made up to 50 µl with RIPA buffer (Pierce). 
NuPAGE 7 % Tris-Acetate Protein Gels were used to resolve the proteins, 5 µl of 
protein ladder (Precision Plus Protein™ Dual Color Standards, Biorad) was loaded in to 
the gel. SDS Running Buffer (NuPAGE) was added to the outer chamber and running  
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FIGURE 2.2 Schematic of air-liquid interface differentiation  
(a) Basal cells were seeded on to membrane inserts with  
0.4 µm pores and cultured in dual SMAD inhibition or Pneumacult- 
Ex plus medium (orange) on the top and bottom chambers until  
they were 100% confluent, after which (b) medium was replaced by 
Pneumacult-ALI medium (yellow). (c) The next day, medium from  
the top chamber was removed to establish air-liquid interface and  





















TABLE 2.3 List of primary antibodies used in immunofluorescence or Western 
blot analysis of ALI-cultured cells 
Antibody Company Host 
Species 
Clone Dilution 
FOXJ1 Invitrogen Mouse 2A5 1:200 
FOXI1 Sigma Rabbit polyclonal 1:200 
ACT Sigma Mouse 6-11B-1 1:1000 
p63 Biocare Mouse 4A4 1:100 
CK5 CST Rabbit D4U8Q 1:200 
MUC5AC Thermo Scientific Mouse 45M1 1:200 
CFTR 596 Cystic Fibrosis 
Foundation 
Mouse A4 1:1000  











TABLE 2.4 List of secondary antibodies used in immunofluorescence or Western 














Company Dilution Fluorophore 
goat anti-mouse goat Invitrogen 1:500 Alexa555 
goat anti-mouse goat Invitrogen 1:500 Alexa488 
goat anti-rabbit goat Invitrogen 1:500 Alexa555 
goat anti-rabbit goat Invitrogen 1:500 Alexa488 
donkey anti-mouse donkey Invitrogen 1:500 Alexa555 
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buffer + antioxidant (NuPAGE) was added to the inner chamber of the electrophoresis 
apparatus. The gel was run for 60 min at 60 V, and then at 100 V for 3 hours. Resolved 
proteins on the gel was transferred onto Hybond-C nitrocellulose transfer membrane 
(Amersham Bioscience) and blocked with 5% non-fat dry milk (in PBS) (blocking buffer) 
at room temperature for 30 minutes. The membrane was then incubated with CFTR 
primary antibody mIgG2b 596 (1:1000; Cystic Fibrosis Foundation Therapeutics) in 
blocking buffer overnight at 4 ºC. After that, the membrane was washed 4 times with 
TBS + 0.1 % Tween 20 + blocking buffer (5 min per wash). This was followed by 
incubation in secondary antibody HRP-linked anti-mouse (1 : 5000, Cell Signaling 
Technologies) in blocking buffer overnight at at 4 ºC, subsequent washing 4 times with 
TBS + 0.1 % Tween 20 + blocking buffer (5 min per wash) and detection by 
chemiluminescense using Amersham ECL Prime.  
2.11 Ussing Chamber Analysis 
        Ussing chamber electrophysiology analyses was done by Dr. Andras Rab (Dr. Eric 
Sorscher lab, Emory University), our collaborator. In brief, membrane inserts were 
mounted in Ussing chambers and chloride ion gradient was established by providing 
low chloride Ringer solution on the apical side, regular Ringer solution on the 
basolateral side. Compounds were added in the following order: 1) amiloride for 10 
minutes (100 µM), apical and basolateral side, 2) forskolin for 5 minutes (10 µM), apical 
and basolateral side, 3) CFTR inhibitor-172 (10 µM), apical side, and 4) UTP (100 µM), 
apical side. The resulting changes in short-circuit current was calculated as ∆Isc. 
2.12 Statistical Analysis  
       We used Microsoft Excel (Seattle, WA, USA) for all our statistical analysis. The 
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Student’s t test was used to determine significance between test and control groups. P-








































3.1 Airway Basal Cell Characterization 
       Airway basal cells express characteristic cell surface markers such as CD49f and 
NGFR. We confirmed the cell surface phenotype of our cultured non-CF and 
∆F508/∆F508 airway basal cells by staining with CD49f and CD271 (NGFR) antibodies 
and fluorescence analysis (FIGURE 3.1). The staining patterns were consistent with 
pure basal cell populations. 
3.2 Analysis of Zinc-Finger Nuclease (ZFN) Activity in Airway Basal Cells 
      Two sets of zinc finger nucleases (ZFNs) (namely ‘exon 11 set 1 ZFN’ and ‘exon 11 
set 2 ZFN’) specific to the CFTR ∆F508 sequence were designed and provided to us as 
plasmid DNA by Sangamo Therapeutics through a collaboration. Each ZFN monomer 
(eg: ZFN-L or ZFN-R) consists of a DNA-binding domain and a FokI-endonuclease 
domain, and following binding of ZFNs to targeted DNA sequences, dimerization results 
in a double-stranded DNA break (DSB). Exon 11 ZFN sets 1 and 2 include a common 
ZFN-left (ZFN-L) component with the DNA-binding domain specific for CFTR ∆F508, but 
not wild-type exon 11 sequence. Each of the ZFN-right (ZFN-R) components of 1 and 2 
recognizes the same target sequences but differ in the amino-acid composition 
(FIGURE 3.2). Achieving reasonable levels of gene correction of CFTR ∆F508 mutation 
via HDR pathway of the cell requires that ZFNs efficiently induce the DSB. Therefore, 
we tested the efficiency of cutting by the ZFNs by assessing the % NHEJ (non-
homologous end joining), also denoted as % INDEL. 




FIGURE 3.1 Basal cell characterization. Basal cells cultured in  
‘dual SMAD inhibition’ medium were characterized for basal  
cell-specific surface markers CD49f and NGFR using fluorescence  
analysis. They were found to be double positive for the two  
markers (Q2) consistent with being pure basal cell populations.  
A) non-CF cells at passage 5. B) CFTR ∆F508/∆F508 cells at  
passage 6. 
                      A) 
                                                      
                       B)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
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RNA (mRNA). ZFN plasmids were used as DNA templates for in vitro production of their 
respective ZFN mRNA generated by in vitro transcription using the T7 promoter. 
Sangamo Therapeutics published a report wherein they showed that inclusion of the 
woodchuck hepatitis virus post-transcriptional response element (WPRE) in the 3’ UTR 
of ZFN mRNA enhanced protein expression of the nuclease and also increased cutting 
efficiency (71). The WPRE sequence increases protein expression by increasing mRNA 
stability and/or increased translation. We therefore assayed the efficiency of the exon 
11 set 1 and 2 ZFNs with and without WPRE. After three days of culturing the cells post 
electroporation, the cells were harvested for genomic DNA (gDNA) isolation. The Cel 1 
assay was performed as a qualitative test to check for ZFN activity. Briefly, PCR 
amplification of the region surrounding the cut site followed by subsequent denaturation 
and renaturation of the amplicon resulted in sequence mismatches (eg: INDEL-∆F508 
and/or INDEL1/INDEL2) which were detected and cleaved by surveyor nuclease 
enzyme. The resulting digested DNA was resolved by gel electrophoresis (FIGURE 
3.3).  An accurate determination of % NHEJ was obtained by high-throughput Next 
Generation Sequencing (NGS) analysis (by our collaborator, Sangamo Therapeutics). 
These data showed that indeed, addition of the WPRE sequence improved efficiency of 
ZFN cleavage (~ 4 – 12 fold) (FIGURE 3.3). The dose responsiveness of ZFN mRNA 
with WPRE sequence was assessed in two independent experiments and the data 
showed an increase in % cutting with increase in ZFN amount (FIGURE 3.4). 





FIGURE 3.2 A) Each ZFN monomer includes a DNA-binding  
domain (blue and orange) and a FokI-endonuclease domain  
(green). After binding of the FokI domains, dimerization results  
in double-stranded DNA breaks (DSB). B) Shown in blue and  
orange are the sequences to which CFTR exon 11 ZFN-L and  
ZFN-R bind, respectively. ZFN-L is specific to the CFTR ∆F508  
mutant sequence.  
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FIGURE 3.3 % NHEJ resulting from the action of ZFN mRNA +/- 
WPRE sequence. A) Primers for Cel 1 assay are shown in purple 
(forward primer) and green (reverse primer). Approximate DNA cut  
site is indicated by a pair of scissors. The resulting DNA sizes upon 
cleavage of mismatches (eg: INDEL-∆F508 and/or INDEL1/INDEL2)  
by surveyor nuclease are ~ 300 and ~100 bp. In an experiment to  
compare % cutting efficiency by ZFN +/- WPRE, 4 µg each ZFN  
mRNA was transfected in to 0.5 million basal cells. B) Results of  
Cel 1 assay. The presence of cleaved DNA indicates ZFN-induced 
INDELs activity. C) NGS analysis quantified the % NHEJ resulting  
from the action of ZFN +/- WPRE. DNA from non-transfected cells  
(no ZFN) was used as a negative control.   
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FIGURE 3.4 Dose response curve of ZFN + WPRE mRNA.  
Two independent experiments were conducted to assess % NHEJ  
resulting from the action of varying doses of ZFN + WPRE mRNA.  
A) EXPT 1:  Results from NGS analysis. % NHEJ was found to  
increase with ZFN amount for both ZFN set 1 and set 2. B) EXPT 2:  
Results from NGS analysis. Similar to that seen in experiment 1,  
% cutting increased with ZFN dose. DNA from non-transfected cells  
were used as negative controls in both experiments. 
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We noticed variation in % NHEJ between experiments and reasoned that it may be due 
to a difference in quality of the mRNA synthesized by in vitro transcription for each  
experiment. Therefore, we purchased large-scale in vitro transcribed ZFN mRNA from 
TriLink Technologies. Exon 11 ZFN set 1 +WPRE (since we did not see much 
difference between the efficiency of set 1 and set 2 ZFNs) was manufactured using the 
plasmid template that we provided to TriLink and this was used in our subsequent 
experiments. To test the efficiency of the commercially-synthesized ZFN, we performed 
a transfection experiment in which varying doses of ZFNs were tested (0.5 - 16 µg each 
ZFN) and % NHEJ was assessed by NGS (FIGURE 3.5). 
3.3 Gene Correction of CFTR ∆F508/∆F508 Airway Basal Cells 
       As noted earlier, gene correction is dependent upon the induction of a DSB 
resulting from the action of ZFNs and the introduction of template DNA carrying the 
correcting sequence. Gene correction of ∆F508 would be evidenced by the addition of 
three bases (CTT) in exon 11 of CFTR. We tested the individual efficiencies of a 100 
and a 200-mer single-stranded oligo donor DNA (ssODN) to facilitate ZFN-mediated 
correction of the CFTR ∆F508 mutation. The 100-mer ssODN and the 200-mer ssODN 
had 50 base homology and 100 base homology on each side of the ZFN cut site, 
respectively (FIGURE 3.6a). In cells receiving 4 µg of each ZFN with either ~2 X 108 or 
~4 X 108 copies of ssODN per cell, % genome modification was assessed 3 days post-
transfection using NGS. With 2 X 108 per cell, % gene correction of 1.3 and 8.1 was 
obtained using the 100 and 200-mer ssODN, respectively. With 4 X 108 copies per cell, 
we obtained a % gene correction of 3.3 and 9.8 using the 100 and 200-mer ssODN, 
respectively (FIGURE 3.6b). This experiment indicated that the 200-mer 
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FIGURE 3.5 Dose response curve of commercially (Trilink)  
in vitro transcribed ZFN + WPRE mRNA. We tested the  
efficiency of TriLink ZFN mRNA using different amounts. Negative  
controls were DNA from non-transfected cells and cells  
transfected with 0.5 µg GFP mRNA. We suspect that decreased % 
NHEJ for 12 µg was perhaps due to experimental error of some 
kind.  
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ssODN resulted in higher % gene correction. We thus proceeded with only the 200-mer 
ssODN.  
3.4 Assessment of CFTR Functional Restoration in Gene Corrected Cells 
        In a subsequent experiment where ~ 4 X 108 copies per cell of the 200-mer ssODN 
(20 µg) and 4 µg of each ZFN mRNA were transfected into cells in duplicate reactions 
(samples denoted as ‘corrected 1’ (C1) and ‘corrected 2’ (C2)), Gene correction 
frequencies of 15.3% and 17.5% were measured at day 3 post electroporation (FIGURE 
3.7). These cells were further expanded and assessed for CFTR functional restoration.         
           Basal cells do not express CFTR and therefore the corrected cells were 
differentiated in vitro using the air liquid interface (ALI) system to give rise to 
differentiated epithelium expressing CFTR. Briefly, basal cells were first cultured on 6.5 
mm Transwell® with 0.4 µm pore polyester membrane insert (Corning) at an initial 
density of ~6000 cells/mm2 in dual SMAD inh medium. After the cells were confluent, 
medium was replaced in the top and bottom chamber with Pneumacult™-ALI medium. 
The next day, medium was removed from the upper chamber and the cells were 
cultured this way for 28 days with daily medium replacement.  
      We observed a decrease in the % genome modification (including both % gene 
correction and % NHEJ) from cells harvested three days post-transfection (‘day 3’ data) 
(e.g.: C1: 68.2 % NHEJ, 15.3 % correction) to those harvested after further expansion 




FIGURE 3.6 Gene correction of CFTR ∆F508/∆F508 basal  
cells. A) The three-base deletion (CTT) (i. e. the CFTR ∆F508  
mutation) is shown in red. We tested the individual efficiencies of  
100- and 200-mer ssODNs to facilitate ZFN-mediated CFTR  
gene correction. Blue indicates corrected sequence. B) Results  
from NGS analysis to assess % NHEJ and % gene correction by  
the ZFN mRNA and 100 or 200-mer ssODN. The 200-mer ssODN  
was found to be more efficient.  
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values obtained in the latter case was more similar to that obtained after 4 weeks of ALI 
differentiation (e.g.: C1: 58.8 % NHEJ, 10.7 % correction) (FIGURE 3.7). 
      RNA was isolated from the ALI-differentiated cells and subsequent complementary 
DNA (cDNA) synthesis followed by reverse-transcriptase PCR (RT-PCR) was 
performed using primers specific to the CFTR cDNA. In the two gene-corrected samples 
(C1, C2), as well as in the mutant controls (with ZFN or oligo), the CFTR cDNA was 
observed to be present. This was as expected since the ∆F508 mutants synthesize 
CFTR mRNA; it is only that protein processing (glycosylation, maturation and transport) 
are impaired. The gene correction frequency for C1 was quite similar for cDNA (10.5%) 
and gDNA (10.7%). Greater differences were observed for C2 (8.5% for cDNA and 
11.1% for gDNA). We have not investigated the reason(s) for similarity versus 
differences between % efficiencies in cDNA versus gDNA. 
       Ussing chamber electrophysiology studies were performed (by our collaborators,  
Drs. Andras Rab and Eric J. Sorscher, Emory University) to assess CFTR functional 
restoration in the in vitro-differentiated corrected cells. In the experiment with samples 
C1 and C2, ∆Isc upon forskolin treatment was measured as 3.2 and 4.7 µA/cm2, 
respectively (and treatment with CFTRinh-172 gave ∆Isc values of -3.3 and -4.4 µA/cm2, 
respectively). The forskolin-induced values were higher than in the mutant controls (p < 
0.05) (FIGURE 3.9). In comparison, non-CF cells showed ∆Isc values of 13.1 µA/cm2 
and -17.3 µA/cm2 upon forskolin and CFTR-inhibitor treatment, respectively. Together, 
this data shows that even modest efficiencies of CFTR gene correction result in 
observable restoration of CFTR ion channel activity.   
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FIGURE 3.7 Gene correction experiment with 4 µg each ZFN  
and 20 µg of the 200-mer ssODN: A) Timeline showing analyses  
done post transfection. B) 0.5 million cells at passage 5 were  
transfected. We obtained 15.3 and 17.5 % in two treated samples 
(denoted as ‘corrected 1’ (C1) and ‘corrected 2’ (C2)) as assessed  
three days-post transfection (day 3). The total % genome modification 
decreased from day 3 to day 7 (i. e. to 8.8% and 11.3% respectively),  
but the values obtained on day 7 were maintained through  
ALI-differentiation (ALI diff.). Negative control included DNA from  
non-transfected mutant cells (no ZFN no ssODN), expanded and  
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FIGURE 3.8. RNA analysis of ALI-cultured cells. A) CFTR  
RT-PCR: Forward and reverse primers flanked exons 10 & 11,  
and exons 13 & 14, respectively. Expected band size was  
581 bp. B) GAPDH RT-PCR: Expected band size was 379 bp.  
‘RT-PCR controls’ for both included PCR reactions without any  
cDNA template. C) Results from NGS analyses of the gDNA  
and cDNA 4 weeks post-ALI differentiation. gDNA from  
ALI-differentiated non-transfected mutant cells (no ZFN no  
ssODN) was used as a negative control here. We do not  
yet have an explanation for the differences in % NHEJ in  
gDNA versus cDNA for sample C1 and the differences in  
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3.5 Isolation of Single-Cell Clones from Bulk-Corrected Basal Cells 
      We then performed single-cell clonal isolation from the bulk population of gene-
corrected basal cells using the conditionally-reprogrammed culture (CRC) methodology 
(72). Briefly, the CRC methodology involves co-culturing of airway basal cell on a feeder 
layer of irradiated mouse fibroblasts together with ROCK inhibitor Y-27362. The 
combination of the fibroblast feeder layer and ROCK inhibitor helps maintain basal cell 
characteristics such as self-renewal, differentiation potential and clone forming ability 
(73).  
      In our single-cell clonal isolation experiment, we seeded a single basal cell from the 
C2 corrected cell population (refer SECTION 3.4 and FIGURE 3.7) into each well of a 
96-well plate containing 30,000 irradiated fibroblasts. Each well was closely monitored 
daily for the appearance of a single-cell derived colony (wells with more than one colony 
were discontinued for further studies). After single-cell derived colonies were greater 
than 50 % confluent, they were isolated using differential trypsinization technique to 
avoid contamination by the fibroblast cells. The isolated basal cells were further 
expanded in dual SMAD inh medium and studied. 60 single-cell clones were isolated, 
out of which 45 reached senescence before they could be analyzed further. The 
remaining 15 clones proliferated up to a time point where their DNA could be analyzed, 
but they also experienced eventual growth arrest by senescence. We first screened the 
15 clones by allele-specific PCR (AS-PCR) using the primer pairs CF1B/CF7C (wild-
type-specific) and CF1B/CF8C (ΔF508-mutant-specific) (FIGURE 3.10). This was 
followed by Sanger sequencing analyses (FIGURE 3.11). Out of the 15 clones that were 
sequenced, 1 was WT/INDEL (clone #27), 5 were INDEL/INDEL, 3 were INDEL/ΔF508,  
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FIGURE 3.9 Ussing chamber analysis of ALI-cultured  
cells. After 4 weeks of ALI differentiation, Ussing chamber  
assays were performed for samples C1 and C2 together  
with controls. Negative controls included no ZFN no ssODN  
and ssODN-alone transfection controls and ZFN-alone control.  
Non-CF cells were used as a positive control. All controls were  
at the same passage and were differentiated at the same time  
as the test samples. A) Upon forskolin activation, the ∆Isc in the  
treated samples C1 and C2 were calculated to be 3.2 and  
4.7 µA/cm2, respectively. These values were significantly different  
(p < 0.05) when compared with the negative controls.  
B) CFTRinh-172 ∆Isc values were determined to be -3.3 and  
-4.4 µA/cm2 for samples C1 and C2, respectively. These values  
were significantly different (p < 0.05) when compared with the  
negative controls. Data are presented as mean ± SD, 8 membrane  
inserts for each condition were analyzed (n=8). * P < 0.05 versus  
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5 were ΔF508/ΔF508, and 1 (clone #2) was amplified neither in the AS-PCR conditions 
nor in the PCR conditions for Sanger sequencing (we predicted this may be due to the 
presence of a large INDEL, but it was not tested further). Although we were successful 
in obtaining only one clone exhibiting correction of the ∆F508 mutation, this result is 
consistent with and verification of site-specific gene correction.  
3.6 Optimization of ZFN Cutting Efficiency in Basal Cells Cultured in 
Pneumacult™-Ex Plus Medium 
    Pneumacult™-Ex plus medium (referred here as ‘P-ex plus medium’ or ‘P-ex plus’) is 
a defined medium produced by Stemcell Technologies for the expansion of primary 
human airway epithelial cells. The manufacturer, in technical materials, provided 
evidence that primary airway basal cells expanded in P-ex plus medium have significant 
proliferative capacity and also retain CFTR function. This led our laboratory to compare 
the proliferative and CFTR activity of basal cells cultured in the P-ex plus medium 
versus dual SMAD inh medium. Dr. Shingo Suzuki of our laboratory showed that basal 
cells in P-ex plus medium had higher proliferative capacity at earlier passages (earlier 
than passage 8) compared to those cultured in dual SMAD inh medium (data not 
shown). Furthermore, cells cultured in P-ex plus followed by ALI differentiation and 
Ussing chamber analyses showed higher CFTR channel activity as a function of 
passage number, as compared to dual SMAD inh cells (data not shown). 
     Conclusions from the study described above led to switching the culture medium for 
basal cells from the dual SMAD inh medium (used in the experiments described thus 
far) to P-ex plus medium. One of the other major reasons to do so was the possibility  
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FIGURE 3.10 Clonal isolation experiment. A) Image at 10x  
magnification showing a basal-cell clone (yellow arrowhead)  
co-cultured with irradiated fibroblasts (seen surrounding the  
clone) B) Shown in purple is the forward primer for the AS-PCR  
we performed, reverse primer specific to CFTR WT sequence is  
shown in blue, and the reverse primer specific to the ΔF508  
sequence is shown in green. The red triangle depicts ΔF508.  
C) 15 clones were screened using AS-PCR, each with a primer  
pair specific to the wild-type allele and a primer pair specific to  
the mutant allele. The expected amplicon sizes were 392 and  
389 bp, respectively. Clone #2 was not amplified in these PCR  
conditions. Wt/wt and mutant/mutant controls were used. Based  
on this screening test, clones # 5, 13, 19, 27 and 60 (**) were  
thought to give possible evidence for at least one wild-type allele.  
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FIGURE 3.11 Clonal isolation experiment: Sanger sequencing  
analysis. A) Clones #5, 13, 19, and 60, although shown to possibly  
have at least one wild-type allele by the AS-PCR, upon sequencing  
were found to be INDEL/mutant, INDEL/INDEL, INDEL/INDEL and 
mutant/mutant, respectively. Clone #27 was confirmed to have one  
allele with wild-type sequence. This was confirmation of site-specific  
gene correction.   









                                
 
 
CLONE # Allele1/Allele2 
27 WT/INDEL 
13 INDEL/ INDEL 
6 INDEL / INDEL 
18 INDEL / INDEL 
19 INDEL / INDEL 
59 INDEL / INDEL 
5 INDEL /∆F508 
55 INDEL /∆F508 








that P-ex plus-cultured basal cells corrected at an early passage could perhaps retain 
their proliferative abilities through clonal isolation (as opposed to the senescence we 
observed) and subsequent expansion for further studies.  
     We tested the % cutting efficiency of ZFN + WPRE mRNA in P-ex plus-cultured 
basal cells. Three identical and independent experiments were conducted. The % NHEJ 
three days post-electroporation was assessed using TIDER analysis (FIGURE 3.12a). 
TIDER is a bioinformatics tool which quantifies % NHEJ and % gene correction using 
Sanger sequence trace decomposition. The total cell number, calculated three days 
post-electroporation for all three experiments, provided information regarding the 
cytotoxicity resulting from electroporation and/or ZFN cutting (FIGURE 3.12b). Based on 
% cutting efficiency and the observation that 4 and 8 µg of each ZFN resulted in greater 
cytotoxicity, we chose 2 µg each ZFN for optimization of gene correction conditions. 
3.7 Optimization of Gene Correction in Basal Cells Cultured in Pneumacult™-Ex 
Plus medium 
      We conducted three identical and independent experiments in which 10, 20 and 30 
µg of the 200-mer ssODN was transfected along with 2 µg each ZFN mRNA. The % 
NHEJ and % gene correction three days post-electroporation was assessed by TIDER 
analysis (FIGURE 3.13a). Cell number at this time point was calculated as a measure of 
cytotoxicity (FIGURE 3.13b). In these optimization experiments, the condition in which 2 
µg each ZFN + 20 µg ssODN were transfected resulted in good frequency of correction 
with acceptable losses in cell number post transfection. Therefore, we decided to test 
this gene correction condition for CFTR functional restoration (FIGURE 3.13c). 
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      Gene-corrected basal cells from experiments 1, 2 and 3 (FIGURE 3.13c) were 
subjected to in vitro differentiation using the ALI system. To visualize pseudostratified 
epithelium in the differentiated gene-corrected cells, hematoxylin and eosin staining 
(H&E staining) was done (FIGURE 3.14). We could observe pseudostratification in the 
corrected cells similar to that observed in the non-CF and ∆F508/∆F508 controls. 
      Immunofluorescence studies using airway epithelial cell type-specific markers were 
performed on the differentiated gene-corrected cells. p63 and CK5 staining were used 
to visualize basal cells, MUC5AC staining for secretory cells, ACT (acetylated-tubulin) 
staining for ciliated cells, and FOXJ1 & FOXI1 staining to visualize ciliated cells and 
ionocytes, respectively (FIGURE 3.15). Comparing the relative quantification of each 
cell type (basal, secretory, ciliated and ionocytes) between the corrected cells and the 
wild-type and mutant controls provided information regarding the effect of genetic 
manipulation on the differentiation capacity of the corrected basal cells (FIGURE 3.16). 
In total, the H&E staining and immunostaining studies show that the in vitro 
differentiation abilities of the corrected basal cells were not observably affected by the 








FIGURE 3.12 ZFN dose response in basal cells cultured in  
P-ex plus medium: A) % NHEJ as assessed by TIDER analysis.  
0.5, 1, 2, 4 and 8 µg of each ZFN were tested for their cutting  
efficiency in three independent and identical experiments. Genomic  
DNA was analyzed three days post transfection. Genomic DNA from  
cells transfected with 1 µg GFP mRNA was used as a negative control.  
Mean values ± SD are presented B) Total cell number three days  
post-transfection were counted from three independent experiments. 
Mean values ± SD are presented.  














                               A) 
                   
                               B) 


























































Amount of each ZFN
63 
 
FIGURE 3.13 Gene correction of CFTR ∆F508/∆F508 basal  
cells cultured in P-ex plus medium. A) % NHEJ and % gene  
correction obtained by TIDER analysis is shown in the graph.  
2 µg of each ZFN mRNA were transfected with 10, 20 and 30  
µg of the 200-mer ssODN; genomic DNA was analyzed three  
days post transfection. This experiment was done in triplicate.  
DNA from cells transfected with 1 µg GFP mRNA was used as  
a negative control. Data are presented as mean ± SD. B) Total  
cell number was counted three days post-transfection for each  
of the three independent experiments in which 2 µg of each ZFN  
mRNA were transfected with 20 µg of the ssODN.  
Mean values ± SD are presented. C) Expt 1, expt 2, and  
expt 3 represent results from three independent experiments.  
These three samples were chosen for further studies.  
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3.8 Demonstration of CFTR Protein Expression and Channel Activity in Gene-
Corrected Cells 
      In the non-CF control, the mature fully-glycosylated CFTR protein was detected 
(~170 kDA) along with the core-glycosylated immature form (~140 kDa) whereas in the 
∆F508/∆F508 control sample, only the core-glycosylated CFTR was detected. This was 
as expected since ∆F508 homozygous cells do not produce mature CFTR. Most 
importantly, we detected the presence of fully-glycosylated CFTR protein (as well as the 
core-glycosylated form) in the corrected in vitro differentiated-cells (FIGURE 3.17).  
      By Ussing chamber analyses, we then assessed CFTR ion channel function 
(FIGURE 3.18). After baseline establishment by amiloride treatment, addition of cAMP-
specific CFTR activator forskolin resulted in increased short-circuit current in the three 
differentiated gene-corrected samples. The ∆Isc values were 8.9, 9.9 and 6.0 µA/cm2, 
respectively. Importantly, these values were greater than that obtained in the ∆F508 
homozygous mutant control (p < 0.05). Furthermore, the use of VX809 + VX770 (the 
components of Orkambi®), an FDA-approved combination drug shown to provide some 
therapeutic benefit to homozygous ∆F508 patients, allowed the comparison of ∆Isc 
values obtained in the corrected cells with an accepted therapeutic range. Although our 
corrected samples yielded higher ∆Isc values than uncorrected ∆F508/∆F508, they did 
not rise to the level of VX809 + VX770-treated samples. Collectively, these data are 
evidence that the gene correction strategy in CF airway basal cells resulted in some 
restoration of CFTR protein expression and ion channel activity, albeit not yet in a 




FIGURE 3.14 H&E staining of ALI-cultured cells: Histology  
studies were done on the ALI-differentiated cells. ZFN + ssODN  
expt 1, 2 and 3represent edited samples from three independent  
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FIGURE 3.15 Immunofluorescence studies of ALI-cultured  
cells:  Representative images are shown at 40X magnification.  
A) CK5 (red) and ACT (green) staining basal cells and cilia,  
respectively. B) MUC5AC (red) and p63 (green) that stain  
secretory cells and basal cels, respectively. C) FOXJ1 (green)  
and FOXI1 (red) staining ciliated cell nuclei and ionocytes,  
respectively. Nuclei were counter-stained with 4,6’-diamidino- 
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                                        B)                
                    Non-CF                
           ∆F508/∆F508                
ZFN + ssODN expt 1               
ZFN + ssODN expt 2               
 ZFN + ssODN expt 3              
p63 MUC5AC DAPI 
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                                        C)                
                    Non-CF                
            ∆F508/∆F508               
   ZFN + ssODN expt 1             
     ZFN + ssODN expt 2            
      ZFN + ssODN expt 3           
FOXJ1 FOXI1 DAPI 
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FIGURE 3.16 Relative quantification of airway epithelial  
cell-types. Followed by immunofluorescence staining with  
markers specific to the cell types, images of 3 random fields  
(n=3) at 40x magnification were acquired. For a particular  
staining, in each of the 3 fields, cell number was counted relative  
to the total cell number (depicted by DAPI staining). Relative  
quantitation of basal cells (A), secretory cells (B), ciliated cells  
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FIGURE 3.17 Western blot analysis of restored CFTR  
protein. Gene corrected cells (ZFN + ssODN expt 1,  
ZFN + ssODN expt 2, ZFN + ssODN expt 3) showed the  
presence of mature fully-glycosylated (~170 kDa) and  
immature core-glycosylated (~140 kDa) CFTR protein in  
contrast to the ∆F508/∆F508 control in which only core- 
glycosylated protein was present. This demonstrates 
restored CFTR protein in gene-corrected cells. Non-CF cells  
showing presence of mature and immature CFTR was used  
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FIGURE 3.18 Ussing chamber analysis of ALI- 
cultured cells: After 4 weeks of ALI differentiation, Ussing  
chamber analysis of CFTR function was performed. Negative  
control included ∆F508/∆F508 cells. Non-CF cells were used  
as a positive control. All controls were at the same passage  
and were differentiated at the same time as the test samples.  
Each of the values obtained upon the action of forskolin and  
CFTR inh-172 in the three test samples were found to be  
greater than that in the negative control (p < 0.05). ΔF508/ΔF508  
cells treated with VX809 + VX770 post-ALI differentiation and  
prior to electrophysiology studies served as a means of  
comparing ∆Isc values obtained in the corrected cells with a  
therapeutic range. Data are presented as mean ± SD, 4  
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   In this study, we aimed to achieve ex vivo genetic correction of the most common 
CFTR mutation ∆F508 in airway basal cells utilizing engineered zinc-finger nucleases 
and single-stranded oligo donor DNA to facilitate gene editing. We specifically focused 
on airway basal cells due to their critical role in maintaining the respiratory epithelium. 
    In a study of DNA double-stranded break-induced gene targeting, it was shown that 
80% of gene-targeting events occurred within 45 bp from the DSB (74). Indeed, 
research groups have reported efficient ZFN-induced gene editing at or within a few bp 
from the DSB (30, 31, 75). In our study, we used ∆F508-specific ZFNs which cut DNA 
~8 bp from the ∆F508 mutation which we wish to restore to wild-type sequence 
(FIGURE 3.2).  We first assessed the efficiency of the ZFNs, delivered in the form of 
mRNA via electroporation, to cause DSB in ∆F508/∆F508 airway basal cells. The 
advantages of delivering ZFN as mRNA as opposed to plasmid DNA are fourfold: 1) 
lower cytotoxicity due to smaller size of RNA, 2) risk of random genome integration is 
eliminated, 3) short half-life of RNA lowers the probability of off-target events, and 4) 
higher cutting efficiency (26). We found that the addition of WPRE in the 3’ UTR of ZFN 
mRNA enhanced % NHEJ ~4 to 12-fold (FIGURE 3.3c), in accordance with previously 
reported findings (71). Consistent INDEL rates were obtained between experiments 
using commercially-produced ZFN mRNA targeting CFTR ∆F508, and they were found 
to be dose-dependent; 25 to 70% NHEJ was achieved, depending on ZFN amount 
(FIGURE 3.5).  
    Donor DNA carrying the correcting sequence is required to facilitate gene correction; 
the length of homology arms is a crucial factor in determining its success rate. Using 
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ZFNs and a donor plasmid or ssODN, several groups had achieved pre-defined 
genomic modifications (26, 30, 31). Using site-specific ZFNs, Chen et al. studied the 
efficacies of a 95-mer ssODN to insert a restriction site in the AAVSI locus in 7 different 
cell types (26). They showed that the ssODN efficiency was cell-type dependent (a 
range of 7 to 57 % insertion rates obtained), and also that the gene modification 
obtained using ssODN was ~two-fold higher than that obtained using a plasmid donor. It 
was reported by George Church et al. (2014) that having the desired mutation at the 
center of the ssODN, preferentially 70-130 bases in length, yielded efficient editing (75). 
Therefore, for ∆F508 gene correction, we aimed to optimize gene correction conditions 
in CF basal cells using ZFNs and a 100- or 200-mer ssODN; in both cases, the desired 
correcting sequence (insertion of CTT) was at the mid-point (FIGURE 3.6A). The 200-
mer ssODN was found to be more efficient, yielding gene correction rates of ~8-10 % 
with 200-400 million copies per cell and thus, was used in our subsequent experiments 
(FIGURE 3.6b). We note that a 10% correction frequency per CFTR allele would imply 
that between 10 and 20% of cells were corrected depending on whether one or two 
alleles were corrected per cell. 
     We achieved 15.3-17.5% correction with transfection of 4 µg of each ZFN mRNA 
and 20 µg of the 200-mer ssODN (2 X 108 copies/cell) (FIGURE 3.7b). Air-liquid 
interface system was used for in vitro differentiation of the corrected basal cells into 
airway luminal cells and the differentiated cells demonstrated partial restoration of 
CFTR channel activity in Ussing chamber assays (ΔIsc values of 3.2 and 4.7 µA/cm2 
after forskolin treatment) (FIGURE 3.9). 
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      We used the CRC technique, in which basal cells are co-cultured with NIH3T3 
mouse fibroblasts along with the ROCK inhibitor Y-27362, to enable single-cell clonal 
isolation from bulk-corrected basal cells (FIGURE 3.10). Pure corrected clones would 
enable us to determine whether correction occurred at one or both alleles. For future 
therapeutic use, it is possible that transplantation of a pure clone would be safer since it 
could be carefully assayed prior to transplantation for unwanted off-target events. From 
our clonal isolation experiment, we obtained one clone having a single wild-type CFTR 
allele, out of the 15 clones (30 CFTR alleles) that were analyzed (FIGURE 3.11). 
Although at low frequency, this was confirmation of site-specific gene correction. The 
clone could not, however, be expanded for further studies due to, we hypothesize, 
senescence at high passage number. A vast majority of the clones we obtained were 
found to have an INDEL in at least one allele. The consequences of an insertion or 
deletion in the immediate vicinity of ΔF508 in exon 11 remains to be determined. This is 
an important issue to consider for in vivo editing since the presence of an INDEL in the 
place of ΔF508 in both alleles could render it insensitive/unresponsive to the CFTR 
triple-drug treatment if eventually utilized as a back-up therapy for the gene editing.  
     We aimed to further improve our gene correction conditions by editing basal cells at 
an earlier passage and by changing the culture medium to increase the proliferation rate 
and better retain CFTR activity with passage number. This change of culture medium 
required us to re-optimize the editing protocol. In the P-ex plus culture conditions, we 
found that the optimum amount of the gene correction reagents that yielded good 
correction efficiency with acceptable levels of cytotoxicity was 2 µg each ZFN mRNA 
and 20 µg of ssODN (FIGURE 3.13). In three independent repeat experiments using 
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these conditions, we obtained correction rates of 7.6-14.2 %. This range of corrected 
alleles imply that we obtained 7.6 to 28.4 % cells that where corrected. The edited cells, 
which is a mixture of corrected and ΔF508/ΔF508 (with or without INDELs), were ALI-
differentiated and immunofluorescence studies, Western blot & Ussing chamber 
analyses were done. 
     Our reason for performing immunofluorescence studies on the corrected cells was to 
check for adverse consequences of gene editing manipulation on the stemness of the 
transfected basal cells. Our results, based on quantification of immuno-stained airway 
epithelial cell types (basal, secretory, ciliated, and ionocytes), demonstrated that the 
differentiation capacities of the manipulated cells were comparable to that of the non-
corrected CF and the non-CF cells (FIGURE 3.16). This is an important assessment 
since CF therapy employing transplantation of edited cells into the airways will rely on 
the stem cell potential of the corrected airway basal cells to repopulate the airway and 
differentiate into luminal cells carrying corrected CFTR. 
     The ΔF508 CFTR protein is pre-maturely degraded in the endoplasmic reticulum and 
therefore only core-glycosylated CFTR protein can be detected in Western blot analysis. 
Indeed, this was the case in our analysis, where the ΔF508/ΔF508 cells showed 
presence of only the immature core-glycosylated CFTR protein (~140 kDa), whereas 
non-CF cells demonstrated presence of both mature fully-glycosylated (~170 kDa) and 
immature CFTR. The gene-edited samples synthesized mature CFTR protein, albeit not 
at the same levels as non-CF controls, as well as its immature form (FIGURE 3.17). 
This provided evidence for the ability of our gene correction method to restore fully-
glycosylated CFTR protein.  
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     Comparison of band intensities in the western blots at various exposure times gave a 
rough estimation of the total mature CFTR synthesized in the corrected cells (the three 
edited replicate samples had 11 – 20.4% of total mature protein as compared to non-CF 
cells, respectively). Since trafficking of the CFTR protein to the cellular apical surface of 
ciliated cells is necessary for its function, CFTR immunofluorescence studies could 
provide information regarding its localization in the corrected cells and the cell types in 
which the protein is predominantly present (i. e. ciliated cells versus ionocytes).  
     By Ussing chamber analysis, we then assessed CFTR ion channel function in the 
three edited differentiated samples.  An increase in chloride current was observed in the 
gene-corrected triplicates when compared with uncorrected CF cells, with the respective 
ΔIsc values upon forskolin treatment 6.0 – 9.9 µA/cm2. However, these values were 
lower than those obtained in the non-CF control cells, or the CF cells treated with the 
VX809 + VX770 drug combination (FIGURE 3.18). These results, although 
encouraging, call for further advances (some discussed below) in our current gene 
editing strategy to achieve a therapeutically relevant gene editing approach for CF.  
      After DSB resulting from the action of nucleases such as ZFNs, the cell 
predominately utilizes the template-independent NHEJ repair pathway to repair the 
lesion. This can be true even in the presence of a donor DNA carrying homologous 
sequences. Thus, there has been some effort to shift the balance to HR-mediated repair 
by specifically inhibiting the NHEJ pathway. Upon inhibiting DNA ligase IV (which is 
required for NHEJ) using SCR7, Hu et al. demonstrated an increase (~two-fold) in Cas9 
and ssODN-directed gene modification in human cancer cells (76). Inhibition of a 
component of the DSB repair system, 53BP1, which is believed to favor NHEJ over 
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HDR, showed an improvement in gene targeting with double-stranded DNA and ZFN by 
~5.6-fold (77). Thus, small molecules and inhibitors such as SCR7 and i53 (inhibitor of 
53BP1) have the potential to enhance gene correction rates and one of the future goals 
of our study could will be to incorporate them to see if they facilitate attaining higher 
editing rates. 
     Another possible avenue for improving ∆F508 editing efficiency would be the delivery 
of the ‘correcting’ donor template. Our current strategy of ssODNs is limited both by 
toxicity of the delivered nucleic acid as well as the limited size of the homology 
sequences. Both limitation could potentially be overcome by donor delivery via viral 
vectors such as adeno-associated virus (AAV). AAV is a single-stranded DNA 
parvovirus and certain serotypes have been shown to have a natural tropism for lung 
epithelium. AAVs can transduce both dividing and non-dividing cells and this is one of 
the major advantages of gene transfer using AAV vectors to the slow-proliferating 
airway epithelium (77 - 82). Ellis et al. (2013) surveyed ex vivo/in vitro transduction 
efficiencies of mammalian primary cells with 10 different AAV serotypes, and they 
demonstrated that AAV6 had the greatest ability to transduce a wide range of cell types 
(84). Efficient HR-driven genome editing in hematopoietic stem cells has been reported 
using ZFN mRNA and AAV6 donors. The relative timings of ZFN and AAV6 delivery are 
a crucial determinant of the efficiency of gene editing and it has been shown that AAV6 
transduction immediately after ZFN electroporation yields most efficient correction rates 
(87). An alternative approach to ssODN-mediated gene correction of CFTR ΔF508 
could, therefore, be transducing AAV6 vectors as homologous donor templates after 
ZFN electroporation. This method of donor DNA delivery could reduce the cytotoxicity 
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we observed in our experiments that resulted from the delivery of ssODNs by 
electroporation. AAV6 vectors could potentially carry larger homology arms (they have a 
maximum genome packaging size of ~4.5 kb) with less toxic effects on the cells and this 
could enhance gene correction to a great extent. 
     CRISPR/Cas9 is emerging as a new powerful system of genome engineering, in 
which the Cas9 DNA nuclease is recruited by a sequence-specific guide RNA (gRNA) to 
its target sequence. After the gRNA binds its specific DNA target through sequence 
complementation, Cas9 induces DSB (89). Nelson et al. had demonstrated successful 
gene correction in a mouse model of Duchenne muscular dystrophy (a genetic disease 
resulting from deletions of one or more exons in the dystrophin gene) using the 
CRISPR/Cas9 system (90). CRISPR-Cas9 mediated correction of CFTR ΔF508 in 
iPSCs has been demonstrated by two groups (91, 92). Therefore, the CRISPR/Cas9 
editing system can be an alternative strategy to the ZFN-mediated gene correction 
of CFTR ΔF508 mutation.  
    One major concern in general for nuclease-mediated genome editing is the possibility 
of off-target events in the genomic DNA. It will, therefore, be imperative to either 
perform whole-genome sequencing on clonal populations or bioinformatically-guided 
NGS on predicted off-target sites in order that the corrected cells may be clinically 
applicable. 
    Accomplishing in vivo CF gene editing would require successful delivery of the editing 
reagents in the context of mucous-clogged CF airways and also reducing/preventing 
host immune responses to gene therapy agents. Clinical translation of the approach 
advanced in this project could take two forms. In the first, one could attempt to directly 
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edit the airway basal cells in vivo. In the second, ex vivo edited airway basal cells (as 
performed in this study, either as a pool of corrected and uncorrected cells or as a 
clonal population of corrected cells) could be transplanted back into the lungs of the 
affected CF patients. This will require transient injury methods to prepare the lung to 
take up the delivered cells. Our achievement in correcting the CFTR ∆F508 mutation 
with demonstration of partial restoration of wild-type protein processing and ion channel 
activity substantiates that gene modification strategies to treat and/or cure CF is 
attainable. With several further improvements, the described correction strategy may 
have the potential to bring us closer to ultimately accomplishing a therapeutic gene 
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